Amyotrophic lateral sclerosis (ALS) progresses to chronic hypercapnic (excessive carbon dioxide) respiratory failure due to chronic hypoventilation. Transcutaneous carbon dioxide (tCO2) monitoring has the potential to advance home care needs in ALS if the size, complexity, and cost of the sensor can be reduced. The aim of this study is to perform clinical validation of a novel tCO2 sensor in the setting of ALS monitoring. Simultaneous measurements of tCO2 will be performed in ALS clinic using the prototype device alongside a commercial device and standard clinical metrics of respiratory function. A group of control participants will also be recruited. Participants will be queried on technology acceptance related to commercial and experimental devices. The clinical study is designed to test 1) the concurrent validity of the prototype wearable against commercial standard and 2) user opinion about the acceptance of this technology as a device for health monitoring.

The study involves a single visit lasting 1.5 hours. You will undergo two 15-minute recordings of CO2 from sensors placed on the skin. These will occur approximately one hour apart. You will then be asked about your experiences during the recordings in a brief interview.

$20

This study will evaluate the safety and efficacy of a novel drug R07790121 compared to placebo in Crohn's disease patients. This drug is an antibody which binds to TL1A, a known important molecule in the regulation of Crohn's disease pathways. The patients who agree to participate and sign the informed consent, will receive a drug or placebo by intravenous infusion on days 0, 2, 6, and 10 of the Induction phase of treatment. During the Maintenance phase of treatment, weeks 12-52, the patients will be randomized to two doses of the drug or placebo that will be given by subcutaneous injection every four weeks. In the Open label phase of treatment, patients will receive the drug every two or every four weeks. All participants will have in-person clinic visits, will be asked to complete daily study questionnaires, provide specimens (stool, blood, urine), and have procedure done (endoscopy, ECG, blood work).

There are two screening visits to find out if subject is eligible to participate. The informed consent must be signed at the first visit, before any procedures. The subjects will be randomized for an induction treatment in two drug arms and one placebo (1:3). The Induction treatment will take 12 weeks and include five visits to the site. They may continue treatment into the Maintenance phase, weeks 12-52, There are ten visits, every four weeks. If disease returns or worsens, the subject may start the open label treatment during the maintenance. Each visit will have blood draws done, vitals check, and some have physical exam.

$75 per completed visit and $50 for travel. Total will depend on the number of visits completed

This study will look to see if radiation plus immunotherapy is better than radiation and chemotherapy.

The participant will either get chemotherapy and radiation therapy for up to 4-7 weeks, or they will get radiation therapy for 4-7 weeks plus the immunotherapy drug, pembrolizumab, given every 6 weeks for about one year (for a total of 9 doses). After the participant finishes the study treatment the study doctor will continue to follow their condition for almost 10 years, either by telephone or clinic visit, and watch them for side effects. The study doctor will monitor the participant every 3 months for 2 years, then every 6 months for 3 years and then annually for 5 years.

This study explores how the brain, eyes, and muscles work together when people use their hands to track or catch moving objects. Participants will sit and use their right hand on a tablet to follow a moving virtual ball while wearing non-invasive sensors that record brain waves (EEG), muscle activity (EMG), and eye movements. The goal is to understand how the body prepares for and responds to motion using vision and movement control. The findings may help scientists improve therapies and technologies for people with movement difficulties, such as after a stroke or brain injury.

Participants will attend one in-person session lasting approximately 2 hours. During the session, they will wear an EEG cap, EMG sensors, and an eye tracker while completing a hand-tracking task using their right hand on a tablet.

20

The proposed research is designed to provide a stronger scientific understanding of the etiology of harsh discipline and the role of parent and child individual and dyadic regulatory processes as potentially malleable mechanisms that underlie and maintain harsh discipline use. The study involves observations of parents and children in the lab and parent questionnaires over multiple time points.

Participation includes two office visits and one online survey, spread out over two years. The first visit occurs when children are 2-3 years old and then again at 4 years old. At these office visits, parents and children complete tasks and play games together, and parents fill out surveys. We will ask you and your child to wear electrode stickers that attach to the skin to measure heart rate and breathing. We will also ask to collect a small hair sample and a few saliva samples from both you and your child throughout the visit. The office visits take approximately 3 hours each. Later, when children turn 5 years old, parents receive an emailed link to a set of online surveys that can be completed at home. It typically takes about 60 minutes to complete the surveys.

$430

This study is comparing 3 arms, one in which patients will participate in Mindfulness (MAPs) Live Online. One in which patients will participate in Mindfulness (MAPs) digitally and one in which patients will participate in the control group, which is meditation only.

Screening visit will be in person. Patients will complete up to 3 hours per week of the assigned activity over a 6-week period. Participation in this study will last about 9 months.

The purpose of this study is to better understand how human teams with non-human virtual agent team members operate and function.

If you agree to be in this study, you will be fitted to sensors that will measure your neurophysiological (i.e., brain and cardiac) signals while you complete group tasks in person or in virtual reality. This interaction will be recorded and coded. You will also be asked to complete several questionnaires about your demographics, behaviors, and emotions.

$25-$40

This is Phase III study to test whether efruxifermin (EFX) helps people with a liver disease called NASH/MASH who have moderate or advanced liver fibrosis. The purpose of the study is to find out whether the study drug works and how safe it is in participants diagnosed with MASH and liver fibrosis over a long-term treatment. To answer these questions, the study drug will be compared with a placebo. The overall study duration will be up to 5 years.

Your participation in the study will last about 4 years and 11 months which includes 3 months for screening procedures (to understand if you are eligible to participate in the study), 4 years and 7 months of study drug treatment and a 30-day follow up at the end of the study. This will involve up to 36 visits to your Study Doctor. During the study, you will be asked to inject a short needle into the soft tissue under the skin (subcutaneous) in the stomach or upper thigh once a week.

Up to $3,500 over the study duration (about 4 years 11 months)

This is a study that will examine the effectiveness of using Art Therapy techniques for improvement and maintenance of self-reported coping skills and symptoms co-occurring with Autism.

The study will last approximately 18 weeks. Participants will be randomly assigned to one of three groups. The assessment only group participants will spend approximately 30 minutes completing online assessments weekly. Participants assigned to the psychoeducational group will meet weekly in person for approximately 45 minutes. Participants assigned to the full art therapy intervention group will meet weekly in person for approximately 1.5 hours. Participants will be asked to complete follow-up assessments at 1 and 3-months after the last week of the assigned group.

The purpose of this clinical research study is to learn more about the use of the investigational drug, deucrictibant, for the prevention of HAE attacks and safety in patients when used in long-term treatment. Investigational drug means that it has not yet been approved in any country for the treatment of HAE. Deucrictibant tablets are designed to block the effects of bradykinin and thus prevent HAE attacks from starting. You will receive deucrictibant tablets for 130 weeks. All participants in the study will receive one 40mg deucrictibant tablet every day. From now onwards, deucrictibant will be referred to as “study drug”. The study drug is a tablet that you will take by mouth. Every day you will have to take 1 tablet with a glass of water, at approximately the same time each day either without a meal or with a light meal. Your study doctor will provide you with detailed instructions on how and when to take the tablets.

There will be approximately 11 in person visits, and approximately 4 virtual visits. At the in person visits, blood will be drawn, EKGs performed, vital signs collected, and the study doctor will perform exams. You will need to complete a daily electronic diary, and take the study medication, an oral pill, daily.

The purpose of this clinical research study is to learn more about the use of the investigational drug, deucrictibant, for the prevention of HAE attacks. You will either receive 40mg deucrictibant or a placebo tablet every day for 24 weeks. The study drug is a tablet that you will take by mouth. Every day you will have to take 1 tablet with a glass of water, at approximately the same time each day either without a meal or with a light meal. The study consists of a Screening Phase which may last up to 10 weeks, a Treatment Phase (24 weeks), and a Follow-up Phase (up to 4 weeks). These are all described below. If you provide your consent to take part in the study and you are declared eligible to participate, your overall study participation will last approximately 10 months (38 weeks).

There will be approximately eight in person visits, blood will be drawn at six of these visits, an EKG will be performed at five of these visits, vital signs will be performed at seven of these visits, and a physical exam will be performed at five of these visits. You will be required to complete questionnaires at each visit, and complete an electronic diary.

Our overall objective is to recruit a case control study of metabolic profiles. We are hoping to learn more about metabolic profiles for people with ALS (Amyotrophic lateral sclerosis - Lou Gehrig’s Disease) and the changes that occur during disease progression. Study participants will be divided into two cohorts: ALS patients and healthy volunteers. The ALS patients will provide blood samples every 6 months, as long as possible. The healthy volunteers will only provide one blood sample upon enrollment in the study.

ALS patients will: - Review and sign informed consent - Attend a study visit lasting 15-30 minutes every 6 months - Provide blood sample every 6 months - Allow study team to access electronic medical record to collect ongoing clinical data at each study visit Healthy volunteers will: - Review and sign informed consent - Attend a single study visit lasting 15-30 minutes - Provide blood sample at enrollment - Provide height & weight - Provide information about Medcial history & medications as they pertain to diabetes and high cholesterol

The purpose of this study is to compare the usual approach to a new technique in radiotherapy delivery called stereotactic body radiotherapy (SBRT) while continuing the current treatment of immunotherapy with or without chemotherapy.

Participants will meet with the study team to discuss the study. After it has been determined that is save for them to enroll, they will need to attend all appointments. Participants will be coming to the clinic at least monthly for infusion therapy and daily for radiation. It is important that participants let the study team know how they are feeling.

The purpose of this study is to improve the treatment of children and young adults with all stages of FHWT, so that more patients are cured without relapse, and that side effects from treatment are lessened without decreasing cure rates. This study will use information on higher or lower risk features of FHWT to adjust the treatment of each subject based on their risk of relapse.

All patients will receive chemotherapy (regardless of stratum assignment) starting with 1 cycle (3 weeks) of VA (vinCRIStine, DACTINomycin) chemotherapy. Some patients will have changes in treatment based on information learned after enrollment. For all patients, at least one callback is required to be completed prior to randomization and/or prior to any change in treatment or continuation of the same treatment.

The purpose of this pilot study is to test women of color's willingness to participate in web- and laboratory-based assessments of their experiences with adversity, their cognition, indicators of poor mental and physical health, risky behaviors during pregnancy, and how they cope with stressful situations. If participants have a 3-to-5-year-old child, we will also ask if they would like their child to participate in various thinking games and biological data collection. If so, we will also assess their preschool-aged child's willingness to participate in various protocols, comprehension of protocol instructions, and ability to complete various tasks.

There will be one in-person visit to the Biobehavioral Health building to collect: -Questionnaires -Height, weight, and waist circumference -Blood pressure -Complete a challenge task -Cognitive tasks -Heart rate monitoring Participants will be asked to complete 7 days' worth of daily assessments on their phone after their in-person study visit. After completing the daily assessments, participants may be selected to participate in a follow-up interview about their experiences throughout the study. Participants will be compensated for their participation in all three portions of the study (in-person visit, daily assessments, and follow-up interview).

$88

The overarching goal of this research is to adapt, optimize, and pilot a transdiagnostic sleep and circadian intervention so that its contents and delivery are effective and sustainable for autistic adolescents

Participants will complete assessments at two time points and engage in a 6 week behavioral sleep intervention with a trained clinician.

$75.00

this trial will compare Pembrolizumab with and without MK-2870 in participants with lung cancer for disease free survival.

Participants will be required to com to all study visits, report all medications they are taking, including over the counter medications and tell the study team how they are feeling.

$50 for each completed visit

This study is being done to answer the following question: Does the use of Olaparib for one year keep your ovarian cancer from growing or returning as well as the usual approach of two years? If you decide to take part in this study, you will either get the study drug Olaparib for one or two years, with or without bevacizumab for one year, until your disease gets worse or the side effects become too severe. After you finish your treatment, your doctor and study team will watch you for side effects. They will check you every 3 months for 2 years after treatment. After that, they will check you every 6 months for 3 years. This means you will keep seeing your doctor for 5 years after treatment.

The patient will either get the study drug Olaparib for one or two years, with or without bevacizumab for one year, until their disease gets worse or the side effects become too severe. The doctor and study team will watch for side effects. They will check every 3 months for 2 years after treatment. After that, they will check every 6 months for 3 years. This means checking with the doctor for 5 years after treatment.

This study will determine how well water, an electrolyte and carbohydrate based drink, and an electrolyte only drink hydrate the body. This study will measure how long the water from these drinks stay in your body. We will look at different hormones and electrolytes in the blood and urine to determine which drink keeps fluid in your body the longest.

There will be 4 in person visits. The first is a screening visit which will take about an hour. During the next three visits we will have you drink 1 L of a beverage and we will measure your blood and urine for a few hours after you drink it to determine how well it hydrates you. There will be a blood draw at each of the 4 visits.

150

This trial will be examining the use of a drug, ifinatamab in the treatment of patients with advanced or metastatic esophageal squamous cell cancer.

After signing consent, participants will have blood tests and scans to see if they are well enough to participate. If the participate, they will need to come to the clinic to see the study team then get the experimental treatment. Participants will continue treatment until the medication no longer works, they no longer want to participate, or the study doctor feels it is not safe for them to continue.

This trial will examine which combination is better in treating Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Sorotoclax or Venatoclax.

There are three parts to this study. Screening, when you will meet the study team, sign the consent for and have tests performed to make sure that it is safe for you to participate in the study. If you join the study you will be chosen to participate in one of four arms, each with different medication to treat you disease. During the first cycle of treatment you will need to be seen by the study team between 4 and 7 times, depending upon the treatment. You will continue on the study medication until it no longer works, you have finished the trial or the doctor feels that it is no safe for your to continue ( among other reasons). The third part of the study is follow up. you will have a study visit in the clinic 30 after the last day of taking the study drug. That will be followed by after treatment follow up visits every three months until your cancer returns, if it returns. Then you will be followed every three months to see how you are doing.

Alopecia areata (AA) is an autoimmune disease that causes non-scarring hair loss that can be relapsing and chronic. It affects patients of all ages, races, and genders. Symptoms can range from patchy hair loss usually affecting the scalp, to complete scalp hair loss (alopecia universalis) or complete loss of hair on the scalp, face, and body (alopecia totalis). AA has a detrimental impact on patients' emotional wellbeing, self-esteem, social interactions, and quality of life, and psychiatric conditions such as anxiety and depression are more common in patients with AA compared to healthy controls. The purpose of this study is to find out if the study medicine, Ritlecitinib, can help with the treatment of AA.

Study participation will last approximately 57weeks. During the study, participants will attend 9 in person visits in the research office. At different timepoints the participant will have their hair examined, blood drawn, have an ECG and chest x-ray done, have photos taken of their scalp and face, answer questionnaires, and take study medication as directed by the study team.

This study will test whether playing pickleball, a fun and easy-to-learn paddle sport, can improve physical coordination and reduce core autism symptoms in adults with autism spectrum disorder (ASD). Participants will be placed in either an early start group or a delayed start group using a delayed control trial design. The early start group will attend two 90-minute pickleball classes per week for the first 8 weeks and then resume regular activities for the next 8 weeks. The delayed start group will continue regular activities for the first 8 weeks and then transition into the pickleball classes for 8 weeks. All participants will complete pickleball skill assessments at their first and last class to measure improvement, and three testing sessions during the study will assess sensory-motor processing, autism symptoms, mental health, and quality of life. By comparing the two groups, this study aims to determine whether pickleball supports better physical and emotional health for autistic adults and whether it can help participants feel more confident, connected, and engaged in social settings.

Participants will attend three in-person testing sessions (baseline, mid-study, and post-study) where they will complete surveys and a videogame-based sensory-motor assessment. They will also participate in two 90-minute coach-led pickleball classes per week for 8 weeks. Pickleball skill assessments will be completed during their first and last pickleball class.

$100

Catheter ablation for patients with atrial fibrillation (AF ablation) is an effective treatment to improve abnormal heart rhythm (i.e., atrial fibrillation, AF). Autonomic nervous system controls things your body does automatically without thinking, such as regulate heart rate, blood pressure, and respiratory control.It has been reported that AF ablation might improve abnormal autonomic nervous system in patients with AF in addition to improve abnormal heart rhythm. However, the detail is still unclear. In the proposed study, we aim to verify the effect of AF ablation on autonomic nervous system in patients with AF. We will evaluate autonomic nervous system using various approaches in AF patients before and after AF ablation, as well as healthy subjects. The results obtained from this study will provide important insights into the research area of AF treatments.

Patients with atrial fibrillation will have three visits to the research lab with each visit lasting 3-3.5 hours. • Visit 1 (pre-AFib ablation): will occur about 1-2 weeks prior to your procedure • Visit 2: approximately 1 month after your ablation procedure • Visit 3: approximately 3 months after your ablation procedure Patients who are healthy volunteers will ONLY have one visit to the research lab that lasts 3-3.5 hours. Various physiological measurements will be recorded during this time including microneurography, blood pressure, heart rate and blood flow.

You will receive $25 per hour for your participation in this research study

This study will aim to see if there is a difference in strength and balance changes among college students when comparing the Wii Fit Balance and whole-body vibration training.

The study duration will be six-weeks, in which study participants will be involved in either a gaming training group or a vibration platform training group. Participants will complete a baseline session and post-training assessment, each lasting two hours. During both of these visits measures of balance, strength, and walking ability will be acquired. In the six weeks of the study,18 individual vibration or gaming training sessions will be completed. The respective training sessions will take place three times a week for 6 weeks and will last 10-minutes each.

$20.00

The purpose of this research study is to determine if a healthy Mediterranean diet containing one medium potato/day has equivalent or non-different effects on risk factors for type 2 diabetes and heart disease as a healthy Mediterranean diet without potatoes. Participants will be randomly assigned to one of the test diets and be asked to consume this diet for 12 weeks (84 days). Testing will be conducted at the beginning and end of the study.

This study runs for about 3 months. During this time, you will be randomly assigned to one of the test diets and be asked to consume this diet for 12 weeks (84 days). We will provide you with all of the food you need to follow this diet. This will include 3 meals, snacks and some beverages prepared in the Penn State Research Kitchen, which will meet your energy and nutrient needs. During the study, we will ask you not to eat any foods outside of those provided by the study. You may have up to 5 days off the diet during the 12 week period. Testing will take place on two separate days at the beginning and end of the study (4 testing days total). For these visits, you will need to fast for 12 hours prior and avoid alcohol for 48 hours. At these visits, we will collect a blood sample, measure your weight, and perform non-invasive tests to assess your vascular health. You will also be asked to wear a continuous glucose monitor (CGM) for 14 days—7 days before the first testing visit and 7 days at the end of the study. The CGM is a small sensor worn on your arm that measures your blood sugar every 15 minutes. You will need to attend a visit to have the CGM fitted (2 visits total). Additionally, we will ask you to collect a stool sample twice during the study.

500

This study aims to support midlife adults by enhancing their emotional well-being and reducing psychological stress, which may affect cardiometabolic health. We are evaluating a novel 4-week program that integrates three components—emotional well-being–enhancing writing, chair-assisted squats, and slow-paced breathing—using a factorial design. Eighty adults aged 40–65 with a sedentary lifestyle will be randomly assigned to one of eight groups that include different combinations of these activities. Participants will engage in their assigned activities via Zoom five times per week over four weeks. Emotional well-being and stress will be assessed through self-report at multiple time points, and physiological health (e.g., blood pressure, heart rate, heart rate variability, inflammation) will be measured during in-person visits before and after the program. The study will also evaluate the feasibility, acceptability, and preliminary effects of each intervention component and their combinations.

Participants will engage in a four-week program involving three components: EWB-enhancing writing exercises, chair assisted squat, and slow-paced breathing. They will complete these activities five times per week, with each session lasting 30 minutes.Participants will undergo cardiovascular assessments at Penn State University’s Biobehavioral Health (BBH) Building at baseline and post-intervention. These assessments will include heart rate variability measured via a standard three-lead electrocardiogram (ECG) and continuous blood pressure measured non-invasively using a finger cuff device that captures beat-to-beat waveforms.

$300

This study is comparing using rilvegostomig or pembrolizumab with a platinum based chemotherapy. The doctor, subject and study team will not know if the subject is receiving rilvegostomig or pembrolizumab.

After signing consent to agree to join the study, the subject will have lab work and scans of their body to see if they are wll enough to participate. If they begin study treatment, they must come to all study visits. It is important that the subject tell the study team if there has been a change in their medications and how they are feeling. Subjects will continue treatment until the treatment no longer is working, they no longer want to participate of the study doctor feels it is not safe for them to participate any further. Once study treatment is finished, subjects will be followed to see how they are feeling and what new treatments for their cancer they are getting.

$75.00 for each visit completed for a minimum of $300. Compensation may be more if additional visits are completed.

The IRB proposal is to conduct research to enhance effectiveness of teaching and learning in college.

Consent for Exempt Research The Pennsylvania State University Title of Project: A Study of Effective Teaching Methods across College Courses Principal Investigator: Yi-An Burleson, Ph.D. Email: ylb5007@psu.edu You are invited to volunteer to participate in a research study. This summary explains information about this research. The study is to collect data to know ways to improve college teaching and learning. Participants will fill out online surveys in teaching and learning in addition to demographic information (e.g. gender, ethnicity, year of study, etc.). It may take 40-50 minutes to complete all of the questions in the surveys. You are strongly encouraged to take the surveys at the beginning of a semester/quarter/term and then at the end of a semester/quarter/term. You are welcome to take the surveys in more than one semester/quarter/term but no more than twice per semester/quarter/term. There may be mild discomfort in feelings, but no risk beyond mild discomfort is involved in the study. If you feel distressed after taking the surveys, you are encouraged to seek counseling resources at college counseling centers. A list of counseling resources is available on request. Other than your email, no other identifying information will be collected. All of the information you provided will be kept confidential by storing it on password protected devices and two-factor authenticated (2FA) online Drive. You can get access through the Sona system/Study Finder of Penn State University. If you are a student at Pennsylvania State University, you can earn 3 points per course by sending an email to indicate that you in the study (with the name of the study), signing up on the Sona system, and indicate that you consent to participate by, clicking “Yes, I consent to participate. My responses to the following questions indicate that I agree to participate” on top of the Google Form at https://forms.gle/H3p2SnErkhpWmYYm7 and then fill out the online surveys at the end of the consent form. You can fill out the survey in the beginning and end of the semester for multiple semesters. If you have questions, complaints, or concerns about the research, you should contact Yi-An Burleson, Ph.D. at ylb5007@psu.edu. If you have questions regarding your rights as a research subject or concerns regarding your privacy, you may contact the Human Research Protection Program at 814-865-1775. Your participation is voluntary and you may decide to stop at any time. You do not have to answer any questions that you do not want to answer.

This is a Phase 3, randomized, double-blind, placebo-controlled study evaluating the clinical benefit and safety of EFX in subjects with compensated cirrhosis due to NASH/MASH. The study will enroll in 2 cohorts. Cohort 1 will enroll approximately 750 subjects with biopsy-proven compensated cirrhosis due to NASH/MASH. Cohort 2 will enroll approximately 400 subjects with a clinical diagnosis of compensated cirrhosis due to NASH/MASH.

You will be required to visit the study clinic at specific times points. Laboratory and safety assessments will be completed at each visit. You will need to take the study drug as directed. Study procedures that will be performed include Liver Imaging scans, Liver Stiffness Exams, Electrocardiogram, Bloodwork, Liver Biopsy and an Endoscopy.